Microbiota-induced plastic T cells enhance immune control of antigen-sharing tumors

Tariq Ahmad Najar, Hao Yuan, Yuhan Hao, Gabriela Romero‐Meza, Alexandra Dolynuk, Dan R. LittmanbioRxiv 2024 · DOI

TL;DR

This paper reveals how a specific gut bacterium, Segmented Filamentous Bacteria (SFB), primes T cells in the gut that can then migrate to distant tumors and enhance the effectiveness of anti-PD-1 immunotherapy. This work highlights the crucial role of gut-primed T cell plasticity in anti-tumor immunity and suggests new avenues for cancer immunotherapy.

What Problem Does This Paper Address?

Cancer immunotherapies, particularly immune checkpoint blockade (ICB) like anti-PD-1, have revolutionized cancer treatment by boosting the immune system's ability to fight tumors. However, a significant portion of patients don't respond to these therapies, and the reasons why are not fully understood. While the gut microbiome is known to influence immune responses and treatment efficacy, the precise mechanisms by which gut bacteria enhance anti-tumor immunity, especially in conjunction with ICB, remain elusive. This study aims to uncover these mechanisms by investigating how a specific gut microbe, SFB, can influence the efficacy of anti-PD-1 therapy against tumors that share antigens with SFB.

Methods

The researchers developed a "synthetic neoantigen mimicry model" by engineering melanoma cells (B16-F10) to express a fragment of an SFB protein (SFB-3340). This allowed them to study how SFB colonization affects the immune response to tumors expressing a shared antigen. Key techniques included:

  • Animal Models: Using mice colonized with SFB or kept SFB-free, and implanting them with either SFB-antigen-expressing tumors (B16-3340) or control tumors (B16-EV).
  • Immunotherapy: Administering anti-PD-1 antibody treatment.
  • T Cell Analysis:
    • TCR Clonal Lineage Tracing: To track the origin and expansion of specific T cell populations.
  • Fate Mapping: Using genetically engineered mice (IL-17A-Cre; ROSALSL-tdTomato) to trace the developmental history of T cells that express IL-17A.
  • Peptide-MHC Tetramer Staining: To identify and quantify antigen-specific T cells.
  • Flow Cytometry: To analyze T cell phenotypes, cytokine production (IFN-γ, TNF-α, IL-17A), and transcription factor expression (T-bet, RORγt, Foxp3).
  • Single-cell RNA Sequencing (scRNA-seq) and TCR sequencing (scTCR-seq): To comprehensively analyze the transcriptomic profiles and TCR repertoires of T cells from different tissues.
  • Depletion Assays: Using antibodies to deplete CD4+ or CD8+ T cells to assess their roles in anti-tumor immunity.

Datasets

Not explicitly discussed as training or evaluation datasets in the context of machine learning. The study relies on experimental data generated from mouse models and various immunological assays.

Key Insights and Ideas

  • Gut-Primed T Cells are Key: The study demonstrates that SFB colonization primes CD4+ T cells in the gut, which then migrate to distant tumors and significantly enhance the efficacy of anti-PD-1 therapy. This highlights the gut as a crucial "training ground" for anti-tumor immunity.
  • T Cell Plasticity is Essential: SFB-induced Th17 cells in the gut undergo a remarkable transformation, becoming Th1-like cells in the tumor microenvironment. This plasticity is critical for their ability to produce pro-inflammatory cytokines and support anti-tumor responses.
  • Antigen Mimicry is Powerful: The use of a synthetic neoantigen mimicry model, where tumor cells express a bacterial antigen, effectively bridges the gap between microbial and tumor immunity, allowing for the study of cross-reactive T cell responses.
  • Synergy Between Microbiota and ICB: The findings underscore a robust synergy between microbiota-induced T cell responses and immune checkpoint blockade, suggesting that manipulating the microbiome could be a powerful strategy to improve immunotherapy outcomes.

Key Results

  • SFB Colonization Enhances Anti-PD-1 Efficacy: Mice colonized with SFB showed significantly reduced tumor growth and improved survival when treated with anti-PD-1 antibody, but only if the tumors expressed the SFB antigen.
  • SFB-Specific Th1-like Cells Emerge in Tumors: Tumor-infiltrating CD4+ T cells in SFB-colonized mice were found to be SFB-specific Th1-like cells, derived from gut-primed Th17 cells.
  • Enhanced CD8+ T Cell Function: These gut-educated ex-Th17 cells promoted the expansion and effector functions of CD8+ tumor-infiltrating lymphocytes, leading to tumor control.
  • CD4+ and CD8+ T Cell Cooperation: Both CD4+ and CD8+ T cells were essential for the anti-tumor effect, with depletion of either cell type significantly compromising anti-PD-1 therapy efficacy.
  • Distinct T Cell Phenotypes: Single-cell sequencing revealed distinct transcriptional profiles and subset distributions of CD4+ T cells in the gut and tumor environments, with a notable shift from Th17 to Th1-like phenotypes in the tumor.

Limitations and Future Work

  • Model System: While the synthetic neoantigen mimicry model is powerful, it's a simplified representation of complex tumor-microbiome interactions. Future work could explore more complex microbial communities and tumor types.
  • Mechanisms of Transdifferentiation: The precise signals and microenvironmental cues that drive the transdifferentiation of Th17 to Th1-like cells in the tumor require further investigation.
  • Generalizability: While SFB is a key focus, understanding how other commensal microbes induce distinct T cell responses and their impact on anti-tumor immunity is crucial for broader therapeutic applications.
  • Human Translation: Translating these findings to human cancer immunotherapy will require further research to identify relevant microbial antigens and T cell responses in patients.

Summary updated

Abstract

ABSTRACT Therapies that harness the immune system to target and eliminate tumor cells have revolutionized cancer care. Immune checkpoint blockade (ICB), which boosts the anti-tumor immune response by inhibiting negative regulators of T cell activation 1–3 , is remarkably successful in a subset of cancer patients, yet a significant proportion do not respond to treatment, emphasizing the need to understand factors influencing the therapeutic efficacy of ICB 4–9 . The gut microbiota, consisting of trillions of microorganisms residing in the gastrointestinal tract, has emerged as a critical determinant of immune function and response to cancer immunotherapy, with multiple studies demonstrating association of microbiota composition with clinical response 10–16 . However, a mechanistic understanding of how gut commensal bacteria influence the efficacy of ICB remains elusive. Here we utilized a gut commensal microorganism, segmented filamentous bacteria (SFB), which induces an antigen-specific Th17 cell effector program 17 , to investigate how colonization with it affects the efficacy of ICB in restraining distal growth of tumors sharing antigen with SFB. We find that anti-PD-1 treatment effectively inhibits the growth of implanted SFB antigen-expressing melanoma only if mice are colonized with SFB. Through T cell receptor clonal lineage tracing, fate mapping, and peptide-MHC tetramer staining, we identify tumor-associated SFB-specific Th1-like cells derived from the homeostatic Th17 cells induced by SFB colonization in the small intestine lamina propria. These gut-educated ex-Th17 cells produce high levels of the pro-inflammatory cytokines IFN-γ and TNF-α, and promote expansion and effector functions of CD8 + tumor-infiltrating cytotoxic lymphocytes, thereby controlling tumor growth. A better understanding of how distinct intestinal commensal microbes can promote T cell plasticity-dependent responses against antigen-sharing tumors may allow for the design of novel cancer immunotherapeutic strategies.
BibTeX
@misc{najar2024microbiota,
  author = {Tariq Ahmad Najar and Hao Yuan and Yuhan Hao and Gabriela Romero‐Meza and Alexandra Dolynuk and Dan R. Littman},
  title = {{Microbiota-induced plastic T cells enhance immune control of antigen-sharing tumors}},
  year = {2024},
  doi = {10.1101/2024.08.12.607605},
  howpublished = {bioRxiv},
}
Figure